Bioequivalence of a New and a Commercial Alprazolam Sublingual Formulation
Status:
Withdrawn
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study tests the hypothesis that the bioavailability of alprazolam from a new sublingual
formulation is the same as that from an existing sublingual formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.